Researchers at WEHI, in collaboration with a team at the University of Vienna, have made a groundbreaking discovery that could have significant implications for the treatment of Parkinson’s disease. The team has identified two proteins that act as regulators for mitophagy, the vital process by which cells recycle damaged mitochondria, the powerhouses of cell energy.
Mitophagy plays a crucial role in maintaining mitochondrial and neuronal health, and its dysfunction has been linked to the development of Parkinson’s disease. This discovery, co-led by Associate Professor Michael Lazarou at WEHI and Professor Sascha Martens at the University of Vienna, marks a new milestone in understanding and potentially boosting mitophagy activity to combat this devastating neurological condition.
Parkinson’s disease is a rapidly growing global health concern, with no current drugs or therapies available to halt its progression. In Australia alone, someone is diagnosed with Parkinson’s roughly every 30 minutes, and this number is expected to double in the next 15 years, surpassing 219,000 cases. The urgent need for effective treatments has prompted WEHI’s Parkinson’s Disease Research Centre to spearhead innovative research efforts with a collaborative, multidisciplinary approach.
New insights into the Parkinson’s pathway
Mitochondria are crucial for generating cellular energy, and their health is maintained through mitophagy, a process orchestrated by key genes PINK1 and Parkin. Mutations in these genes have been associated with early-onset Parkinson’s disease, underscoring the importance of understanding how mitophagy is regulated.
Previously, the mechanisms behind PINK1/Parkin mitophagy activation were unclear until the discovery of NAP1 and SINTBAD, two proteins identified in the recent study published in Nature Structural and Molecular Biology. The research revealed that NAP1 and SINTBAD regulate the threshold for mitophagy activation, shedding light on a previously unknown aspect of mitochondrial quality control.
According to Associate Professor Michael Lazarou, this finding broadens our understanding of mitophagy regulation and presents a promising target for potential drug therapies. Modulating NAP1 and SINTBAD in neurons could lower the activation threshold, thereby enhancing mitophagy and promoting mitochondrial and neuronal health.
Implications for Parkinson’s patients
Individuals living with Parkinson’s disease face a challenging reality, as current treatments focus on symptom management rather than disease modification. The lack of disease-modifying therapies emphasizes the urgent need for innovative research endeavors, such as the identification of NAP1 and SINTBAD, to develop targeted treatments.
This groundbreaking research, supported by Aligning Science Across Parkinson’s (ASAP) and the Rebecca Cooper Medical Research Foundation, holds promise for advancing drug discovery efforts and creating new therapeutic avenues for neurodegenerative conditions like Parkinson’s. Collaborating with WEHI’s National Drug Discovery Centre, researchers aim to translate these findings into practical strategies for developing novel therapies.
